BRPI0415198A - composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii - Google Patents

composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii

Info

Publication number
BRPI0415198A
BRPI0415198A BRPI0415198-4A BRPI0415198A BRPI0415198A BR PI0415198 A BRPI0415198 A BR PI0415198A BR PI0415198 A BRPI0415198 A BR PI0415198A BR PI0415198 A BRPI0415198 A BR PI0415198A
Authority
BR
Brazil
Prior art keywords
angiotensin
receptor
pharmaceutical composition
selective imidazoline
receptor agonist
Prior art date
Application number
BRPI0415198-4A
Other languages
English (en)
Inventor
Dominique Baum
Gerhard-Wilhelm Bielenberg
Bernd Boedecker
Dirk Thormaehlen
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BRPI0415198A publication Critical patent/BRPI0415198A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM AGONISTA SELETIVO DO RECEPTOR DA IMIDAZOLINA I1 E UM BLOQUEADOR DO RECEPTOR DA ANGIOTENSINA II". A presente invenção refere-se a composições farmacêuticas compreendendo agonistas seletivos do receptor da imidazolina combinados com bloqueadores do receptor da angiotensina II. Em particular, a presente invenção refere-se a composições farmacêuticas compreendendo Moxonidina e mesilato de Eprosartan. A invenção também refere-se à utilização das referidas composições na preparação de um medicamento para o tratamento da hipertensão, de um modo particular, em doentes hipertensos que já sofram de diabetes do tipo II ou que estão suscetíveis de desenvolver diabetes do tipo II.
BRPI0415198-4A 2003-10-10 2004-10-07 composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii BRPI0415198A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103763 2003-10-10
PCT/EP2004/052468 WO2005039639A2 (en) 2003-10-10 2004-10-07 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker

Publications (1)

Publication Number Publication Date
BRPI0415198A true BRPI0415198A (pt) 2006-12-05

Family

ID=34486329

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415198-4A BRPI0415198A (pt) 2003-10-10 2004-10-07 composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii

Country Status (19)

Country Link
US (2) US20050143435A1 (pt)
EP (1) EP1673107B1 (pt)
JP (1) JP4829115B2 (pt)
KR (1) KR101137084B1 (pt)
CN (1) CN100453117C (pt)
AT (1) ATE390148T1 (pt)
AU (1) AU2004283047B2 (pt)
BR (1) BRPI0415198A (pt)
CA (1) CA2541867C (pt)
DE (1) DE602004012763T2 (pt)
ES (1) ES2304624T3 (pt)
IL (1) IL174762A (pt)
MX (1) MXPA06004029A (pt)
NO (1) NO335735B1 (pt)
PL (1) PL1673107T3 (pt)
RU (1) RU2362561C2 (pt)
UA (1) UA83077C2 (pt)
WO (1) WO2005039639A2 (pt)
ZA (1) ZA200601804B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
US20090156579A1 (en) * 2005-10-25 2009-06-18 Hasegawa Philip A Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension
ATE499090T1 (de) 2006-06-16 2011-03-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
EP2018885B1 (en) 2007-07-25 2011-02-09 Schott forma vitrum ag Application device
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
SG177426A1 (en) * 2009-06-30 2012-02-28 Sanofi Sa Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
CN102850331B (zh) * 2012-09-17 2015-05-20 符爱清 一种化合物的制备方法
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
RU2734281C1 (ru) * 2019-06-11 2020-10-14 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы
EP3986412A4 (en) * 2019-06-21 2023-11-15 The Broad Institute, Inc. Agents for reversing toxic proteinopathies
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
EP4731195A1 (en) 2023-06-26 2026-04-29 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5354867A (en) * 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
JP2707390B2 (ja) * 1992-05-22 1998-01-28 壽製薬株式会社 シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
HU0200980D0 (pt) * 2002-03-14 2002-05-29 Gabor S Pal Dr
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
NO20062088L (no) 2006-07-07
JP2007508276A (ja) 2007-04-05
KR101137084B1 (ko) 2012-04-24
RU2362561C2 (ru) 2009-07-27
US20050143435A1 (en) 2005-06-30
ATE390148T1 (de) 2008-04-15
JP4829115B2 (ja) 2011-12-07
EP1673107A2 (en) 2006-06-28
RU2006115796A (ru) 2007-11-27
HK1096293A1 (zh) 2007-06-01
EP1673107B1 (en) 2008-03-26
ES2304624T3 (es) 2008-10-16
PL1673107T3 (pl) 2008-06-30
WO2005039639A2 (en) 2005-05-06
UA83077C2 (ru) 2008-06-10
MXPA06004029A (es) 2006-06-28
WO2005039639B1 (en) 2005-09-22
AU2004283047B2 (en) 2009-09-17
CA2541867A1 (en) 2005-05-06
DE602004012763D1 (de) 2008-05-08
IL174762A0 (en) 2006-08-20
CN100453117C (zh) 2009-01-21
CA2541867C (en) 2012-06-12
ZA200601804B (en) 2007-05-30
KR20060117912A (ko) 2006-11-17
US20110229571A1 (en) 2011-09-22
AU2004283047A1 (en) 2005-05-06
CN1859924A (zh) 2006-11-08
DE602004012763T2 (de) 2009-05-07
NO335735B1 (no) 2015-02-02
IL174762A (en) 2010-11-30
WO2005039639A3 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
BRPI0415198A (pt) composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1993560A4 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
DK2049475T3 (da) Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
SG165314A1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
MX2007009389A (es) Agonistas de pyy y sus usos.
EA201270169A1 (ru) Агонисты gpr119
MX2009008534A (es) Antagonistas novedosos del receptor de glucagon.
MXPA06011924A (es) Dispositivo de liberacion continua base polimeros.
TW200730202A (en) Solid dosage form
AR037065A1 (es) Una composicion farmaceutica en base a bloqueadores de receptores 5ht3 y 5ht4, inhibidores de la bomba de protones y antagonistas de receptores de h2, util para tratar los desordenes gastrointestinales
EP1824812A4 (en) AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
EP1549655A4 (en) SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе
TW200722088A (en) Diabetes remedy
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
GB0111220D0 (en) Restricting reinstatement of drug use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ABBOTT PRODUCTS GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]